AU2014312261A1 - Combination of an ALK inhibitor and a CDK inhibitor for the treatment of cell proliferative diseases - Google Patents

Combination of an ALK inhibitor and a CDK inhibitor for the treatment of cell proliferative diseases Download PDF

Info

Publication number
AU2014312261A1
AU2014312261A1 AU2014312261A AU2014312261A AU2014312261A1 AU 2014312261 A1 AU2014312261 A1 AU 2014312261A1 AU 2014312261 A AU2014312261 A AU 2014312261A AU 2014312261 A AU2014312261 A AU 2014312261A AU 2014312261 A1 AU2014312261 A1 AU 2014312261A1
Authority
AU
Australia
Prior art keywords
compound
combination
alk
inhibitor
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2014312261A
Other languages
English (en)
Inventor
Jennifer Leslie Harris
Nanxin LI
Timothy R. Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2014312261A1 publication Critical patent/AU2014312261A1/en
Priority to AU2017219093A priority Critical patent/AU2017219093A1/en
Priority to AU2018236813A priority patent/AU2018236813A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2014312261A 2013-08-28 2014-08-28 Combination of an ALK inhibitor and a CDK inhibitor for the treatment of cell proliferative diseases Abandoned AU2014312261A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2017219093A AU2017219093A1 (en) 2013-08-28 2017-08-25 Combination of an ALK inhibitor and a CDK inhibitor for the treatment of cell proliferative diseases
AU2018236813A AU2018236813A1 (en) 2013-08-28 2018-09-27 Combination of an ALK inhibitor and a CDK inhibitor for the treatment of cell proliferative diseases

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361871275P 2013-08-28 2013-08-28
US61/871,275 2013-08-28
PCT/US2014/053244 WO2015031666A1 (en) 2013-08-28 2014-08-28 Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017219093A Division AU2017219093A1 (en) 2013-08-28 2017-08-25 Combination of an ALK inhibitor and a CDK inhibitor for the treatment of cell proliferative diseases

Publications (1)

Publication Number Publication Date
AU2014312261A1 true AU2014312261A1 (en) 2016-03-10

Family

ID=51541330

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2014312261A Abandoned AU2014312261A1 (en) 2013-08-28 2014-08-28 Combination of an ALK inhibitor and a CDK inhibitor for the treatment of cell proliferative diseases
AU2017219093A Abandoned AU2017219093A1 (en) 2013-08-28 2017-08-25 Combination of an ALK inhibitor and a CDK inhibitor for the treatment of cell proliferative diseases
AU2018236813A Abandoned AU2018236813A1 (en) 2013-08-28 2018-09-27 Combination of an ALK inhibitor and a CDK inhibitor for the treatment of cell proliferative diseases

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2017219093A Abandoned AU2017219093A1 (en) 2013-08-28 2017-08-25 Combination of an ALK inhibitor and a CDK inhibitor for the treatment of cell proliferative diseases
AU2018236813A Abandoned AU2018236813A1 (en) 2013-08-28 2018-09-27 Combination of an ALK inhibitor and a CDK inhibitor for the treatment of cell proliferative diseases

Country Status (12)

Country Link
US (2) US20160361314A1 (https=)
EP (1) EP3038652B1 (https=)
JP (1) JP6479812B2 (https=)
KR (1) KR20160047521A (https=)
CN (1) CN106029099A (https=)
AU (3) AU2014312261A1 (https=)
BR (1) BR112016004358A8 (https=)
CA (1) CA2922684A1 (https=)
ES (1) ES2674361T3 (https=)
MX (1) MX2016002580A (https=)
RU (1) RU2016110874A (https=)
WO (1) WO2015031666A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101772134B1 (ko) 2015-04-14 2017-08-29 한국화학연구원 N2-(2-메톡시페닐)피리미딘 유도체, 이의 제조 방법 및 이를 유효 성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
WO2016167511A2 (ko) * 2015-04-14 2016-10-20 한국화학연구원 N2-(2-메톡시페닐)피리미딘 유도체, 이의 제조 방법 및 이를 유효 성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
WO2017112948A1 (en) * 2015-12-24 2017-06-29 University Of Florida Research Foundation, Inc. Improved aav production using suspension adapted cells
US11395821B2 (en) 2017-01-30 2022-07-26 G1 Therapeutics, Inc. Treatment of EGFR-driven cancer with fewer side effects
EP3738084A4 (en) 2018-01-08 2021-11-17 G1 Therapeutics, Inc. SUPERIOR G1T38 DOSING SCHEMES
EA202192575A1 (ru) 2019-03-21 2022-01-14 Онксео Соединения dbait в сочетании с ингибиторами киназ для лечения рака
EP3947368B1 (en) * 2019-04-04 2025-09-03 Dana-Farber Cancer Institute, Inc. Bifunctional compounds comprising a cdk2/5 ligand, a linker and a e3 ubiquitin ligase binding degron for the treatment of cancer
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
JP7642556B2 (ja) 2019-11-18 2025-03-10 中外製薬株式会社 併用医薬
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
TW202146017A (zh) * 2020-03-05 2021-12-16 美商輝瑞股份有限公司 間變性淋巴瘤激酶抑制劑及周期蛋白依賴型激酶抑制劑之組合
US20230381176A1 (en) * 2020-09-25 2023-11-30 Ascentage Pharma (Suzhou) Co., Ltd. A pharmaceutical composition and use thereof for treatment of cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ577197A (en) * 2006-12-08 2011-02-25 Irm Llc Pyrimidine compounds especially 4-phenylamino-2-arylamino-pyrimidine derivatives and compositions as protein kinase inhibitors
EA017405B9 (ru) * 2006-12-08 2014-05-30 АйАрЭм ЭлЭлСи Соединения и композиции в качестве ингибиторов протеинкиназы
ES2522346T3 (es) * 2008-08-22 2014-11-14 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de CDK
JP2012526850A (ja) * 2009-05-13 2012-11-01 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル サイクリン依存性キナーゼ阻害剤及びその用法
EP2558092B1 (en) * 2010-04-13 2018-06-27 Novartis AG Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase 6 (cdk4/6) inhibitor and an mtor inhibitor for treating cancer
RS54189B1 (sr) * 2011-02-02 2015-12-31 Novartis Ag Postupci za korišćenje inibitora alk

Also Published As

Publication number Publication date
WO2015031666A1 (en) 2015-03-05
JP2016529285A (ja) 2016-09-23
US20160361314A1 (en) 2016-12-15
US20180318305A1 (en) 2018-11-08
EP3038652B1 (en) 2018-03-21
ES2674361T3 (es) 2018-06-29
AU2018236813A1 (en) 2018-10-18
JP6479812B2 (ja) 2019-03-06
CA2922684A1 (en) 2015-03-05
KR20160047521A (ko) 2016-05-02
AU2017219093A1 (en) 2017-09-14
CN106029099A (zh) 2016-10-12
RU2016110874A (ru) 2017-10-04
EP3038652A1 (en) 2016-07-06
RU2016110874A3 (https=) 2018-06-27
BR112016004358A8 (pt) 2020-02-11
MX2016002580A (es) 2016-10-26

Similar Documents

Publication Publication Date Title
US20180318305A1 (en) Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases
TWI758623B (zh) Ｂｃｌ-２抑制劑與ＢＴＫ抑制劑的組合產品在預防和/或治療疾病中的用途
CA2827673C (en) Mtor/jak inhibitor combination therapy
CN113474337A (zh) 作为fgfr抑制剂用于治疗癌症的7-((3，5-二甲氧基苯基)氨基)喹喔啉衍生物
AU2013341271A1 (en) Combination therapy
KR20160020502A (ko) 제약 조합물
AU2019226212A1 (en) Combination of Pl3K inhibitor and c-Met inhibitor
US20220202814A1 (en) Treatment of cancer
KR20120097496A (ko) 조합물
CN118159534A (zh) 抑制PI3K同工型α的化合物和用于治疗癌症的方法
KR20160090814A (ko) Jak, cdk 및 pim의 억제제를 포함하는 조합 요법
US12233047B2 (en) Pharmaceutical combination and use thereof
CN117479943A (zh) 组合疗法中的egfr抑制剂和perk活化剂及其用于治疗癌症的用途
US20260053785A1 (en) Combination therapy for treatment of cancer
WO2024173833A1 (en) Combination of a cdk inhibitor and a flt3 inhibitor for the treatment of cancer
HK40127969A (zh) 包含bcl-2抑制剂或bcl-2/bcl-xl抑制剂的组合产品及其用途
HK40109492A (zh) 包含bcl-2抑制剂或bcl-2/bcl-xl抑制剂的组合产品及其用途
HK40035225A (en) Pharmaceutical combination and use thereof
HK40060213A (en) 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
US20180256557A1 (en) Pharmaceutical combination comprising (a) the alpha-isoform specific pi3k inhibitor alpelisib (byl719) and (b) an akt inhibitor, preferably mk-2206, afuresertib or uprosertib, and the use thereof in the treatment/prevention of cancer

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted